$COSMJun 10, 2026, 7:32 PMAI processed
COSM: Cana inks 3-year deal to make 3.9M VASCLOR GEST progesterone pessaries for Verisfield
AI Summary
Cosmos Health's subsidiary Cana Laboratories signed a three-year contract manufacturing agreement with Verisfield to produce 1.3M units per year (3.9M total) of VASCLOR GEST (progesterone 400mg) vaginal pessaries for luteal phase support/assisted reproduction. The deal expands Cana's contract-manufacturing footprint into women's health using its EU GMP-certified facilities and aims to grow its high-margin manufacturing division, but the company did not disclose pricing or expected revenue so the financial impact is unclear.
Positives
- Three-year contract to manufacture 1.3M units annually (3.9M units total) of VASCLOR GEST 400mg pessaries
- Expands Cana's contract manufacturing into women’s health and reproductive medicine, diversifying its order book
- Manufacturing will be done in EU GMP-certified facilities, supporting the company's push to grow its high-margin contract manufacturing segment
Negatives
- Company did not disclose pricing or revenue guidance, so dollar impact is unknown
- Total confirmed volume is 3.9M units over three years, a finite and relatively short-duration order
- Three-year term limits long-term visibility for this revenue stream